glp 1 gip triple agonist Hitting the G Spot: The New Triple G for Weight Loss The clinically most relevant mechanisms
Description
Effects of exenatide (exendin-4) on glycemic control and weight over 30 weeks in metformin-treated patients with type 2 diabetes
Consequently, patients with T2DM often exhibit reduced Pdx1 expression levels (Ofori et al., 2022)
38 ZanderMMadsbadSMadsenJLHolstJJ
They require medical evaluations, lab work, and ongoing monitoring
Results Baseline characteristics We identified 42,816 subjects treated with metformin in combination with either GLP-1 RAs (n = 16,723) or DPP-4is (n = 26,093)
95% CI, 0.51 1.08), the latter having been demonstrated to have neutral effect on cardiovascular outcomes (263)
